LONDON--(BUSINESS WIRE)--Technavio research analysts have predicted the global chemotherapy-induced neutropenia therapeutics market to grow at a CAGR of around 6% during the period 2018-2022, according to their latest report.
The increase in global awareness about cancer treatments is a major trend being witnessed in the market. The awareness about cancer and cancer-related issues has increased mainly because of the continuing efforts of different organizations. Several organizations are collaborating to spread awareness about chemotherapy in underdeveloped regions. Major vendors in this market have also helped patients in undergoing chemotherapy.
This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing
Save more with Technavio. Buy 2 reports and get the third for FREE: View all Technavio’s current offers
In this report, Technavio analysts highlight the rising number of patients opting for chemotherapy as a key factor contributing to the growth of the global chemotherapy-induced neutropenia therapeutics market:
Rising number of patients opting for chemotherapy
Cancer is counted among the top five causes of death across all age groups in the world. It is estimated that in 2014, approximately 1.6 million new cases of cancer were registered in the US and around 600,000 individuals succumbed to the disease. The most common cancers are breast cancer, leukemia, prostate cancer, lung cancer, cervical cancer, pancreatic cancer, colorectal cancer, ovarian cancer, Hodgkin’s disease, and non-Hodgkin lymphoma. Many of these are curable, particularly when treated at early stages. However, most of these are fatal without treatment.
According to a senior analyst at Technavio for oncology, “Many patients choose chemotherapy as a preferred choice of treatment for cancer over other methods such as surgery or radiation because chemo drugs travel through the bloodstream and have a widespread effect throughout the body.”
Looking for more information on this market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Chemotherapy-induced neutropenia therapeutics - segmentation analysis and forecast
This market research report segments the global chemotherapy-induced neutropenia therapeutics market by procedure (G-CSF therapy, granulocyte transfusion, antibiotic therapy, and splenectomy) and key regions (the Americas, APAC, and EMEA). It provides an in-depth analysis of the prominent factors influencing the market, including the prominent drivers, opportunities, trends, and industry-specific challenges.
The Americas was the leading region for the global chemotherapy-induced neutropenia therapeutics market in 2017, accounting for a market share of more than 40%. This region is expected to dominate the market throughout the period 2018-2022.
Save big with Technavio this May!
Find out what companies are venturing in to beat the heat this summer! Technavio indulges you with a massive 20% OFF on all
beverages reports for the entire month.
Technavio honors the achievements and efforts of Motherhood this Mother's Day by offering a whopping 30% OFF on all cosmetics and toiletry reports. Offer valid from 7th May for a limited period.
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at firstname.lastname@example.org.